NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present clinical data on its lead asset, Plinabulin, at three upcoming scientific conferences:
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity Society
(Chandler, Ariz. – Oct. 14 through 16, 2018 – The Sheraton Grand at Wild Horse Pass)
Abstract No. 89
Title: “Plinabulin-Associated Neutrophil Demargination: Evidence for a Clinically Relevant Mechanism of Action for the Prevention of Chemotherapy-Induced-Neutropenia”
Date / Time: Session I, Oct. 15, 11 a.m. to 1 p.m. local time
European Society for Medical Oncology (ESMO) 2018 Congress
(Munich, Germany – Oct. 19 through 23, 2018 – Messe Munich)
Presentation No. 1686PD
Title: “Plinabulin (Plin), a Novel non-G-CSF Molecule for the Prevention of Chemotherapy-Induced Neutropenia (CIN), has the Potential to Positively Impact Tumor Micro Environment”
Date / Time: Hall B3 – Room 21, ICM München, Oct. 22, 4:30 p.m. local time
Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(Washington, D.C. – Nov. 7 through 11, 2018 – Walter E. Washington Convention Center)
Abstract No. P495
Title: “Pegfilgrastim, but not Plinabulin, generates a blood myeloid cell (BMC) repertoire with a predominant immunosuppressive phenotype”
Date / Time: Nov. 9, 12:45 to 2:15 p.m. and 6:30 to 8 p.m. local time
“Having the opportunity to present a stream of quality data for Plinabulin over the coming weeks at these influential conferences is a testament not only to the dedication of our team at BeyondSpring but also to our strong belief that the Company’s lead product candidate has the potential to address a high unmet medical need for patients all over the globe in the very near-term,” said Dr. Lan Huang, CEO, BeyondSpring. “We look forward to continuing to advance through the clinic and bringing Plinabulin to market as quickly and efficiently as possible.”
Plinabulin, a marine-derived small-molecule, is BeyondSpring’s lead asset and currently in late-stage clinical development for the prevention of CIN and as an anticancer therapy in NSCLC. Studies of Plinabulin’s mechanism of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to up-regulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia by reducing the neutrophil breakdown.
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using a ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Laura Perry / Joe Rayne